LAVAL, QC, Aug. 8, 2017 /CNW Telbec/ - Prometic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today
announced that it will report its financial results for the second
quarter ended June 30, 2017 on
Monday August 14, 2017 after market
close.
Prometic will host a conference call at 11:00am (ET) on Tuesday
August 15, 2017. The telephone numbers to access the
conference call are 1-888-231-8191 and 647-427-7450. A live audio
webcast of the conference call will be available
via: http://event.on24.com/r.htm?e=1479907&s=1&k=35DE47AF154E64327899FF3DF5DB6903
An audio replay of the call will be available as of Tuesday August 15, 2017 at 2:00pm (ET). The numbers to access the audio
replay are 416-849-0833 and 1-855-859-2056 using the following
password (65097120).
About Prometic Life Sciences Inc.
Prometic Life Sciences Inc. (www.prometic.com) is a
long-established biopharmaceutical company with globally recognized
expertise in bioseparations, plasma-derived therapeutics and
small-molecule drug development. Prometic is active in
developing its own novel small-molecule therapeutic products
targeting unmet medical needs in the field of fibrosis, cancer and
autoimmune diseases/inflammation. A number of plasma-derived and
small molecule products are under development for orphan drug
indications. Prometic also offers its state of the art technologies
for large-scale purification of biologics, drug development,
proteomics and the elimination of pathogens to a growing base of
industry leaders and uses its own affinity technology that provides
for highly efficient extraction and purification of therapeutic
proteins from human plasma in order to develop best-in-class
therapeutics and orphan drugs. Headquartered in Laval (Canada), Prometic has R&D facilities
in the UK, the U.S. and Canada, manufacturing facilities in the UK
and commercial activities in the U.S., Canada, Europe and Asia.
Forward Looking
Statements
This press release contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in
Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and
Uncertainties related to Prometic's business". As a result,
we cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by
applicable securities laws and regulations. All amounts are
in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.